GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: LY-2062430
Compound class:
Antibody
Comment: Solanezumab is an investigational humanized monoclonal antibody targeting amyloid-β (Aβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. The invention of solanezumab is covered by patent US7195761 [2], where it is coded as Hu266. |
| References |
|
1. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS et al.. (2014)
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med, 370 (4): 311-21. [PMID:24450890] |
|
2. Holtzman DM, DeMattos R, Bales KR, Paul SM, Tsurushita N, Vasquez M. (2007)
Humanized antibodies that sequester abeta peptide. Patent number: US7195761. Assignee: Eli Lilly And Company, Washington University. Priority date: 24/02/2002. Publication date: 27/03/2007. |
|
3. Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F. (2012)
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol, 8 (2): 135-49. [PMID:22288451] |
|
4. Tayeb HO, Murray ED, Price BH, Tarazi FI. (2013)
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?. Expert Opin Biol Ther, 13 (7): 1075-84. [PMID:23574434] |
